Metastatic breast cancer treatment aims to control cancer growth, relieve symptoms, preserve daily function, and help patients live as well as possible. Treatment is personalized according to hormone receptor status, HER2 status, genetic changes, previous treatments, affected organs, symptoms, and overall health.
Metastatic breast cancer, also called stage 4 breast cancer, has spread beyond the breast and nearby lymph nodes to distant areas such as the bones, liver, lungs, or brain. Although it is generally not considered curable, modern systemic therapies may control the disease for meaningful periods.
Metastatic Breast Cancer Treatment
Treatment usually involves medicines that travel throughout the body. Options include hormone therapy, targeted therapy, chemotherapy, immunotherapy, antibody-drug conjugates, and PARP inhibitors. Radiation therapy, surgery, and bone-strengthening medicines may also be used for selected symptoms or complications.
| Cancer subtype or feature | Possible treatment approach |
| HR-positive, HER2-negative | Hormone therapy with a CDK4/6 inhibitor |
| HER2-positive | HER2-targeted therapy, often with chemotherapy or another targeted drug |
| HER2-low or HER2-ultralow | Certain HER2-directed antibody-drug conjugates |
| Triple-negative, PD-L1 positive | Pembrolizumab with chemotherapy in eligible patients |
| Inherited BRCA1 or BRCA2 mutation | PARP inhibitor |
| PIK3CA, AKT1, PTEN or ESR1 alteration | Biomarker-directed targeted or endocrine therapy |
| Bone metastases | Systemic treatment, radiation and bone-modifying medicine |
| Brain metastases | Radiation, surgery or drugs with activity in the brain |
This table is a simplified overview. Treatment selection and sequencing require individual assessment by an oncologist.
What Is Metastatic Breast Cancer?
Metastatic breast cancer develops when breast cancer cells travel through the blood or lymphatic system and form tumors in distant organs. Cancer found in the liver or bones remains breast cancer because the cells originated in the breast.
Some people have stage 4 breast cancer when first diagnosed. Others develop recurrent metastatic breast cancer months or years after completing treatment for an earlier-stage tumor.
Common sites of breast cancer metastasis include the bones, liver, lungs, and brain. The location of metastases can affect symptoms and influence how urgently treatment must begin.
How Treatment Is Selected?
The oncology team considers more than the location of the cancer. Important factors include estrogen receptor (ER), progesterone receptor (PR), HER2 status, menopausal status, symptoms, previous treatment, organ function, and how quickly the disease is progressing.
Whenever possible, doctors may biopsy a metastatic tumor because its biomarkers can differ from those found in the original breast cancer. Blood-based liquid biopsy may sometimes identify treatment-relevant genetic changes when tissue testing is difficult.
Testing may examine:
- ER and PR hormone receptors
- HER2-positive, HER2-low or HER2-ultralow status
- PD-L1 expression
- Inherited BRCA1 and BRCA2 variants
- PIK3CA, AKT1, PTEN and ESR1 alterations
- Other actionable mutations found through genomic testing
These results support personalized treatment for metastatic breast cancer and may reveal eligibility for targeted medicines or clinical trials.
Treatment for HR-Positive, HER2-Negative Cancer
Hormone receptor-positive, HER2-negative disease may respond to endocrine therapy, which blocks estrogen or reduces its production. Common medicines include aromatase inhibitors, fulvestrant, tamoxifen, and newer estrogen receptor-targeting drugs.
For many patients, initial treatment combines hormone therapy with a CDK4/6 inhibitor. This approach can delay cancer growth while often avoiding the immediate need for chemotherapy.
When cancer becomes resistant, testing may identify an ESR1, PIK3CA, AKT1, or PTEN alteration. The result can help the oncologist select another endocrine or targeted therapy. For example, the FDA approved imlunestrant for certain ER-positive, HER2-negative cancers with an ESR1 mutation after progression on endocrine therapy.
Chemotherapy or an antibody-drug conjugate may be considered when endocrine treatments stop working, symptoms require a faster response, or the cancer affects vital organ function.
Treatment for HER2-Positive Metastatic Breast Cancer
HER2-positive tumors produce high levels of a growth-promoting protein called HER2. HER2-targeted medicines can block this signal or deliver treatment directly to cancer cells.
Options may include trastuzumab, pertuzumab, trastuzumab deruxtecan, tucatinib, and other HER2-directed medicines. The exact sequence depends on previous treatment, heart function, brain metastases, and drug availability.
In December 2025, the FDA approved trastuzumab deruxtecan with pertuzumab as a first-line option for eligible adults with unresectable or metastatic HER2-positive breast cancer. Because recommendations continue to change, patients should discuss the latest available first-line options with their oncology team.
Treatment for HER2-Low and HER2-Ultralow Disease
Some tumors are not HER2-positive but still display small amounts of the HER2 protein. These are classified as HER2-low or, under newer testing definitions, HER2-ultralow.
This distinction matters because some antibody-drug conjugates may work in these cancers. Trastuzumab deruxtecan is FDA-approved for selected HR-positive, HER2-low or HER2-ultralow metastatic breast cancers that have progressed after endocrine therapy.
Accurate pathology review is important because an older report marked “HER2-negative” may not include the details now used to determine HER2-low or ultralow status.
Triple-Negative Metastatic Breast Cancer Treatment
Triple-negative breast cancer lacks ER, PR, and HER2 biomarkers. Therefore, traditional hormone and HER2-targeted therapies do not work against it.
Chemotherapy remains an important treatment. For tumors with sufficient PD-L1 expression, pembrolizumab may be combined with chemotherapy in eligible patients. NCI reports that this combination improved survival for certain patients with PD-L1-positive advanced triple-negative breast cancer.
Other options may include antibody-drug conjugates such as sacituzumab govitecan, PARP inhibitors for inherited BRCA mutations, and clinical trials. The choice depends on biomarkers, prior therapy, disease speed, symptoms, and organ function.
PARP Inhibitors for BRCA-Related Breast Cancer
People with an inherited BRCA1 or BRCA2 mutation may be eligible for a PARP inhibitor. These medicines interfere with cancer cells’ ability to repair damaged DNA.
Olaparib and talazoparib are approved for selected patients with BRCA-associated metastatic breast cancer. Genetic counselling can help patients understand testing results and possible implications for relatives.
Chemotherapy and Antibody-Drug Conjugates
Chemotherapy may be used for any metastatic breast cancer subtype, particularly when targeted or endocrine treatments are unsuitable or no longer effective. Doctors often use one medicine at a time to balance cancer control with side effects.
Antibody-drug conjugates combine a targeting antibody with a cancer-killing medicine. They are designed to deliver treatment more directly to cells carrying a particular target.
Options depend on subtype and previous treatment. Datopotamab deruxtecan, for example, is approved for selected HR-positive, HER2-negative metastatic breast cancer after prior endocrine therapy and chemotherapy.
Radiation Therapy and Surgery
Systemic therapy is the main treatment because metastatic cancer affects the whole body. Surgery and radiation are usually used for specific problems rather than as the only treatment.
Radiation may relieve painful bone metastases, control bleeding, treat brain lesions, or reduce pressure on nerves or the spinal cord. Surgery may stabilize a weakened bone, remove a threatening brain lesion, or address a painful local breast tumor in selected cases.
Local treatment of a small number of metastases, called oligometastatic disease, is being studied. It is not automatically appropriate for everyone with limited metastatic disease.
Managing Bone and Brain Metastases
Bone-modifying medicines such as bisphosphonates or denosumab may reduce fractures and other skeletal complications. Dental evaluation may be recommended because these medicines can rarely damage the jawbone.
Brain metastasis treatment can include stereotactic radiation, whole-brain radiation, surgery, systemic therapy, or a combination. The number, size, location, symptoms, and tumor subtype guide the plan.
New headaches, seizures, weakness, confusion, speech changes, or vision problems require prompt medical evaluation.
Side Effects and Supportive Care
Treatment side effects vary widely. Possible concerns include fatigue, nausea, low blood counts, infection, diarrhea, mouth sores, nerve damage, heart changes, blood clots, liver problems, or lung inflammation.
Patients should report new symptoms early rather than waiting for the next appointment. Dose adjustments, treatment breaks, supportive medicines, rehabilitation, nutrition support, and pain management can make therapy safer and more manageable.
Palliative care can begin alongside cancer treatment. It focuses on controlling pain, breathlessness, fatigue, sleep problems, emotional distress, and caregiver burden. Receiving palliative care does not mean cancer treatment is stopping.
Monitoring Treatment Response
Doctors may use CT, MRI, PET, or bone scans to evaluate disease. Blood tests help monitor the liver, kidneys, blood counts, calcium, and treatment toxicity.
Tumor-marker blood tests may provide additional information in some patients, but they are generally interpreted alongside symptoms and imaging. One abnormal marker result does not necessarily mean treatment has failed.
Treatment may continue while it controls the cancer and side effects remain acceptable. If the disease progresses, the oncology team may change medicines, repeat biomarker testing, or discuss a clinical trial.
Outlook and Living With Metastatic Disease
Metastatic breast cancer is generally treated as a long-term, life-limiting illness rather than a curable condition. However, responses vary greatly, and some people live for years while moving through several effective treatments.
Prognosis depends on cancer subtype, metastatic sites, treatment response, general health, and available therapies. Population survival statistics cannot predict an individual patient’s outcome.
Practical support may include symptom tracking, financial counselling, mental health care, advance care planning, physical therapy, and assistance for caregivers. These services can be used while active treatment continues.
When to Seek Emergency Medical Care
Contact the oncology team urgently or seek emergency care for:
- Fever during chemotherapy or another immune-suppressing treatment
- Sudden difficulty breathing or chest pain
- New seizure, severe headache, confusion, or one-sided weakness
- New severe back or neck pain
- Leg weakness, numbness, difficulty walking, or loss of bladder control
- Uncontrolled bleeding
- Repeated vomiting or inability to keep fluids down
- Sudden severe pain in a bone or inability to bear weight
- Yellow skin, extreme sleepiness, or rapidly increasing abdominal swelling
New back pain with weakness, numbness, or bladder or bowel changes may indicate metastatic spinal cord compression, which is a medical emergency.
Questions to Ask the Oncologist
- What are my current ER, PR, HER2 and HER2-low results?
- Should the metastatic site be biopsied?
- Which genetic or genomic tests could change my treatment?
- What is the goal of the recommended therapy?
- How will we determine whether it is working?
- Which side effects require an urgent call?
- Are brain or bone-directed treatments needed?
- Is a clinical trial appropriate now or later?
- When should palliative care become involved?
- What treatments may be available if this one stops working?
Conclusion
Metastatic breast cancer treatment is selected according to tumor subtype, biomarkers, previous therapy, metastatic location, symptoms, and patient priorities. Options may include hormone therapy, HER2-targeted treatment, chemotherapy, immunotherapy, antibody-drug conjugates, PARP inhibitors, radiation, and supportive care.
Treatment continues to evolve, making repeat biomarker testing and updated oncology advice valuable. A personalized plan can help control stage 4 breast cancer, manage symptoms, and protect quality of life.
FAQS
Yes. Although it is generally not considered curable, treatment may shrink tumors, slow cancer growth, relieve symptoms, and support quality of life for meaningful periods.
First-line treatment depends on HR and HER2 status, genetic changes, previous therapy, symptoms, affected organs, menopausal status, and how quickly the cancer is progressing.
No. HR-positive disease may initially be treated with hormone therapy and targeted medicine. Chemotherapy may be used when endocrine therapy is unsuitable or faster disease control is needed.
Treatment generally includes HER2-targeted medicines, sometimes combined with chemotherapy or another targeted drug. The sequence depends on prior treatment, brain metastases, and current approvals.
Options may include chemotherapy, immunotherapy for eligible PD-L1-positive disease, antibody-drug conjugates, PARP inhibitors for BRCA mutations, and clinical trials.
Some patients achieve a complete response in which tests show no detectable cancer. Treatment and monitoring usually continue because microscopic cancer cells may remain.
A new biopsy confirms metastatic disease and checks whether ER, PR, or HER2 status has changed. Updated results may reveal different treatment options.
A treatment commonly continues while it controls the cancer and side effects remain manageable. Doctors may change it when cancer progresses or toxicity becomes unacceptable.
Radiation can control selected tumors, relieve bone pain, treat brain metastases, reduce bleeding, and protect the spinal cord. It is usually combined with systemic therapy.
Clinical trials may provide access to emerging treatments and help improve future care. Eligibility depends on cancer subtype, biomarkers, prior therapies, health, and trial requirements.